It is important to consider the relative efficacy of the available therapies for RVO with published data. This systematic review was therefore performed to assess the efficacy and safety of ...

VEGF is a mediator in the pathogenesis of certain eye conditions, including wet age-related macular degeneration (AMD), diabetic retinopathy and macular oedema secondary to retinal vein occlusions.

AAO: American Academy of Ophthalmology; CSME: Clinically significant macular edema; DR: Diabetic retinopathy; NHMRC: National Health and Medical Research Council; NPDR: Nonproliferative DR ...

Safety and the mean change in best-corrected visual acuity (BCVA) from baseline to week 52 in the study eye, measured using ...

Diabetic retinopathy and diabetic macular oedema are serious complications of diabetes, which can lead to complete loss of vision. Traditional treatments for diabetic retinopathy and diabetic ...

People with diabetes are at a greater risk of developing eye conditions that can lead to blindness, such as diabetic retinopathy and diabetic macular oedema. Vision loss due to diabetes-related ...

Like Lucentis, the biosimilar can also be used to treat proliferative diabetic retinopathy (PDR), macular oedema caused by retinal vein occlusion (RVO) and visual impairment due to choroidal ...

The trial was sponsored by the US government-funded National Institutes of Health (NIH) and the Diabetic Retinopathy ... related macular degeneration (AMD) and Diabetic Macular Oedema by ...